Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43874   clinical trials with a EudraCT protocol, of which   7293   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004964-25
    Sponsor's Protocol Code Number:ABY-035-203
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-07-15
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-004964-25
    A.3Full title of the trial
    A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in
    the treatment and prevention of relapse/recurrence of non-infectious intermediate,
    posterior or pan-uveitis, including an initial pilot phase (LINNAEA)
    Estudio de fase II sobre la eficacia y la seguridad del inhibidor de la interleucina-17A ABY-035 en el tratamiento y la prevención de la recidiva/recurrencia de panuveítis o uveítis intermedia o posterior no infecciosa, incluyendo una fase preliminar inicial
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.
    Estudio multinacional, multicéntrico, de fase 2, sobre la eficacia y la seguridad de ABY-035 en el tratamiento y la prevención de la recaída/recurrencia de la actividad de la enfermedad en sujetos con uveítis intermedia, posterior o pan-uveítis no infecciosa.
    A.3.2Name or abbreviated title of the trial where available
    LINNAEA
    A.4.1Sponsor's protocol code numberABY-035-203
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04706741
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAffibody AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAffibody AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAffibody AB
    B.5.2Functional name of contact pointRegulatory Affairs
    B.5.3 Address:
    B.5.3.1Street AddressScheeles väg 2
    B.5.3.2Town/ citySolna
    B.5.3.3Post codeSE-171 65
    B.5.3.4CountrySweden
    B.5.4Telephone number+46 (0) 763495849
    B.5.5Fax number+46 8 59 88 38 01
    B.5.6E-mailcamilla.sandell@affibody.se
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code ABY-035
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIzokibep
    D.3.9.1CAS number 2226130-02-3
    D.3.9.2Current sponsor codeABY-035
    D.3.9.3Other descriptive nameRecombinant protein comprising two IL-17A binding domains and an albumin binding domain
    D.3.9.4EV Substance CodeSUB201240
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    non-infectious intermediate, posterior, or pan-uveitis
    la uveítis intermedia, posterior o pan-uveítis no infecciosa
    E.1.1.1Medical condition in easily understood language
    non-infectious intermediate, posterior, or pan-uveitis
    la uveítis intermedia, posterior o pan-uveítis no infecciosa
    E.1.1.2Therapeutic area Diseases [C] - Eye Diseases [C11]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10046851
    E.1.2Term Uveitis
    E.1.2System Organ Class 10015919 - Eye disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part A: To evaluate the efficacy of ABY-035 in treating active uveitis from Baseline (BL) up to week 10 (W10) with subsequent possible adaptation of the design in Part B
    Part B: To investigate the efficacy of ABY-035 in preventing relapse/recurrence in inactive uveitis from trial beyond W10 up to W50
    Parte A: evaluar la eficacia de ABY-035 en el tratamiento de la uveítis activa desde el inicio (INI) hasta la S10 con la posterior adaptación del diseño en la Parte B
    Parte B: investigar la eficacia de ABY-035 en la prevención de la recidiva/recurrencia de la uveítis inactiva desde después de la semana 10 (S10) del ensayo hasta la S50
    E.2.2Secondary objectives of the trial
    • To evaluate the safety of ABY-035
    • To characterize the exposure of ABY-035 in plasma
    • To assess the immunogenicity of ABY-035
    • To investigate the efficacy of ABY-035 in treating active uveitis from BL up to W10
    - Evaluar la seguridad de ABY-035
    - Caracterizar la exposición de ABY-035 en el plasma
    - Evaluar la inmunogenicidad de ABY-035
    - Investigar la eficacia de ABY-035 en el tratamiento de la uveítis activa de INI hasta la S10
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1] Signed informed consent and signed data protection declaration
    2] ≥18 years of age at SCR
    3] Previously documented medical history with diagnosed unilateral or bilateral NIIPPU
    4] Active disease at BL defined by the presence of at least 1 of the following criteria in at least one eye
    despite treatment with stable doses of corticosteroids for at least 2 weeks:
    a) Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion by dilated indirect ophthalmoscopy (DIO), fundus photography, fluorescein angiography (FA), Spectral-Domain Optical Coherence Tomography (SD-OCT) to determine whether a lesion is active or inactive (the central reader’s assessment using FA, fundus photography and/or SD-OCT is required to confirm eligibility).
    b) ≥2+ vitreous haze ( NEI/SUN criteria) by DIO and Fundus Photography (the central reader’s
    assessment using Fundus Photography is required to confirm eligibility).
    5] On treatment with oral corticosteroids (≥7 to ≤40 mg/day oral prednisolone/pre dnisone or
    equivalent) at a stable dose for at least 2 weeks before BL
    6] For females of non-childbearing potential: Post-menopausal or surgically sterile
    7] For females of childbearing potential: Negative human chorionic gonadotropin (hCG) test at SCR
    visit AND practicing adequate contraception (see section 7.1.7) from SCR to FUpreg (section 6.2.6)
    8] For males: if having a female partner, the partner should be of non-childbearing potential (see
    inclusion criteria 6) OR using an adequate method of contraception (see section 7.1.7) from SCR to
    FUpreg (see 6.2.6)
    9] Able and willing to comply with the trial directives (as per the investigator's judgment)
    1.Firma del consentimiento informado y de la declaración de protección de datos
    2.≥18 años de edad en la SEL
    3.Antecedentes médicos confirmados de diagnóstico previo de NIIPPU unilateral o bilateral.
    4.Enfermedad activa al INI definida por la presencia de al menos 1 de los siguientes criterios en al menos un ojo a pesar del tratamiento con dosis estables de corticosteroides durante al menos 2 semanas:
    a.Lesión vascular retiniana inflamatoria coriorretiniana inflamatoria activa según oftalmoscopia indirecta con dilatación pupilar (OIDP), fotografía del fondo de ojo y angiografía con fluoresceína (AF) Tomografía de coherencia óptica de dominio espectral (TCO-DE) para determinar si una lesión es activa o inactiva (la evaluación del evaluador central mediante AF y/o fotografía del fondo de ojo y/o (TCO-DE) es necesaria para confirmar la elegibilidad).
    b.Turbidez del humor vítreo ≥2+ (criterios del Instituto Ocular Nacional NEI/SUN) mediante OIDP y fotografía del fondo de ojo (la evaluación del evaluador central mediante la fotografía del fondo de ojo es necesaria para confirmar la elegibilidad).
    5.En tratamiento con corticosteroides orales (de ≥7 a ≤40 mg/día de prednisolona/prednisona o equivalente) a una dosis estable durante al menos 2 semanas antes del INI.
    6.Mujeres sin capacidad de procrear: posmenopáusicas o esterilizadas quirúrgicamente.
    7.Mujeres con capacidad de procrear: resultado negativo en la prueba de determinación de la gonadotropina coriónica humana (hCG) en la visita de SEL Y utilizar un método anticonceptivo aceptable (véase el apartado 7.1.7) desde la SEL hasta el SEGemb (véase el apartado 6.2.6)
    8.Hombres: en caso de tener una pareja femenina, esta no debe tener capacidad para procrear (véase el criterio de inclusión 6) O debe utilizar un método anticonceptivo aceptable (véase el apartado 7.1.7) desde la SEL hasta el SEGemb (véase el apartado 6.2.6)
    9.Capaz de cumplir las directivas del ensayo y dispuesto a hacerlo (según el criterio del investigador)
    E.4Principal exclusion criteria
    1] History of hypersensitivity or allergy to ABY-035 or its excipients
    2] History of hypersensitivity or allergy to fluorescein dye
    3] Previous enrollment or randomization in the trial
    4] Participation in another interventional clinical trial within 30 days before SCR or administration of
    another IMP within 5 half-lives (for experimental biologics: 6 months or 5 half-lives, whichever is
    longer) before BL
    5] Evidence or suspicion of social drug and/or alcohol abuse or dependence, according to the judgment
    of the investigator
    6] Females who are currently pregnant, who intend to become pregnant during the trial, or who are
    breastfeeding
    7] The subject is an investigator or belongs to the personnel of the trial site, the sponsor or involved
    service providers and/or their immediate families (partner, spouse, parent, child, or sibling, whether
    biological or legally adopted)
    8] Subject with any medical or psychiatric condition which, in the investigator's opinion, would
    preclude the subject from adhering to the protocol or completing the clinical trial per protocol
    9] The subject is considered to belong to a vulnerable population (e.g. placed under guardianship,
    imprisoned, other)
    Criteria that relate to ocular conditions (and the etiology thereof)
    10] Subject with isolated anterior uveitis
    11] Subject with Occlusive Behçet's disease, Acute Posterior Multifocal Placoid Pigment
    Epitheliopathy, Acute Posterior Pigment Epithelitis, Multiple Evanescent White Dot Syndrome,
    Punctate Inner Choroiditis or serpiginous choroidopathy
    12] Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis
    due to TB, syphilis, cytomegalovirus, Lyme disease, toxoplasmosis, Human T-Lymphotropic Virus
    Type 1 infection, Whipple's disease, herpes zoster virus, and herpes simplex virus
    13] Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires
    cataract surgery during the duration of the trial
    14] Planned (elective) eye surgery within 80 weeks after BL
    15] History of prior refractive laser surgery, retinal laser photocoagulation, or neodymium-doped
    yttrium aluminium garnet posterior capsulotomy within 30 days before BL
    16] History of any other prior ocular surgery within 90 days before BL
    17] Subject with intraocular pressure (IOP) of ≥25 mmHg while on ≥2 glaucoma medications or
    evidence of glaucomatous optic nerve injury
    18] Subject with severe vitreous haze that precludes visualization of the fundus at BL
    19] Subject has a contraindication for mydriatic eye drops OR subject cannot be dilatated sufficiently
    well to permit good fundus visualization
    20] Subject with BCVA <20 letters (ETDRS) in at least one eye at BL
    21] Subject with intermediate uveitis or panuveitis who has presence or history of whitish exudates on
    the inferior pars plana (snowbanking) or vitreal inflammatory aggregates (snowballs) in combination
    with a medical history or signs or symptoms suggestive of a demyelinating disease such as multiple
    sclerosis
    22] Subject with proliferative or severe non-proliferative diabetic retinopathy or clinically significant
    macular edema due to diabetic retinopathy
    23] Subject with neovascular/wet age-related macular degeneration
    24] Subject with an abnormality of the vitreo-retinal interface (i.e., vitreomacular traction, epiretinal
    membranes, etc.) with the potential for macular structural damage independent of the inflammatory
    process
    25] Subject with a history of active scleritis within 12 months of SCR
    Criteria that relate to comorbidity
    26] Uncontrolled inflammatory bowel disease
    27] Infection requiring treatment with IV anti-infectives within 30 days before BL or oral anti-infectives
    within 14 days before BL
    28] Subject with any active infection that based on the investigator's clinical assessment makes the
    subject an unsuitable candidate for the trial
    29] History or any signs of lymphoproliferative disease, or a known malignancy or a history of
    malignancy within the previous 3 years (except for basal cell or squamous cell carcinoma of the skin
    that had been fully excised with no evidence of recurrence)
    1.Antecedentes de hipersensibilidad o alergia a ABY-035 o a sus excipientes.
    2.Antecedentes de hipersensibilidad o alergia al colorante de fluoresceína.
    3.Inclusión o aleatorización previa en el ensayo.
    4.Participación en otro ensayo clínico de intervención en los 30 días anteriores a la SEL o administración de otro medicamento en investigación (MI) en un periodo de 5 semividas (en caso de productos biológicos experimentales: 6 meses o 5 semividas, lo que sea más largo) antes del INI.
    5.Indicio o sospecha de abuso o dependencia de drogas o alcohol, según el criterio del investigador.
    6.Mujeres embarazadas actualmente, que tengan intención de quedarse embarazadas durante el ensayo o que estén amamantando.
    7.El paciente es un investigador o pertenece al personal del centro del ensayo, al promotor o a los proveedores de servicios implicados y/o a sus familias inmediatas (pareja, cónyuge, padre, madre, hijo/a o hermano/a, ya sea biológico/a o legalmente adoptado/a).
    8.Paciente con algún tipo de trastorno médico o psiquiátrico que, en opinión del investigador, le impediría cumplir el protocolo o finalizar el ensayo clínico de acuerdo con el protocolo.
    9.Se considera que el paciente pertenece a una población vulnerable (p. ej., legalmente tutelado, en prisión, otras circunstancias).
    Criterios relacionados con afecciones oculares (y su etiología)
    10.Paciente con uveítis anterior aislada.
    11.Paciente con enfermedad oclusiva de Behçet, epiteliopatía pigmentaria placoide multifocal posterior aguda, epitelitis pigmentaria posterior aguda, síndrome de múltiples puntos blancos evanescentes, coroiditis punteada interna o coroidopatía serpiginosa.
    12.Paciente con confirmación o sospecha de uveítis infecciosa, incluidas, entre otros, uveítis infecciosa debida a tuberculosis (TB), sífilis, citomegalovirus, enfermedad de Lyme, toxoplasmosis, virus T-linfotrópico humano de tipo 1, enfermedad de Whipple, virus del herpes zóster y virus del herpes simple.
    13.Paciente con opacidad corneal o del cristalino que impide la visualización del fondo de ojo o que probablemente requiera cirugía de cataratas durante el ensayo.
    14.Cirugía ocular programada en las 80 semanas posteriores al INI.
    15.Antecedentes de cirugía refractiva previa con láser, fotocoagulación retiniana con láser o capsulotomía posterior con láser de neodimio-itrio-aluminio-granate en los 30 días previos al INI.
    16.Antecedentes de cualquier otra cirugía ocular previa en los 90 días anteriores al INI.
    17.Paciente con presión intraocular (PIO) ≥25 mm Hg durante el tratamiento con ≥2 medicamentos contra el glaucoma o signos de lesión glaucomatosa del nervio óptico.
    18.Paciente con turbidez intensa del humor vítreo que impide la visualización del fondo de ojo al INI.
    19.Paciente con una contraindicación para recibir el colirio midriático O que no puede dilatar lo suficientemente bien para permitir una buena visualización del fondo de ojo.
    20.Paciente con mejor agudeza visual corregida (MAVC) <20 letras (estudio de tratamiento precoz de la retinopatía diabética [ETDRS]) en al menos un ojo al INI.
    21.Paciente con uveítis intermedia o panuveitis con presencia o antecedentes de exudados blanquecinos en la porción plana inferior (en banco de nieve) o agregados inflamatorios en el vítreo (bolas de nieve) en combinación con antecedentes médicos o signos o síntomas indicativos de enfermedad desmielinizante como esclerosis múltiple.
    22.Paciente con retinopatía diabética proliferativa o no proliferativa grave, o edema macular clínicamente significativo debido a retinopatía diabética.
    23.Paciente con degeneración macular neovascular/húmeda asociada a la edad.
    24.Paciente con una anomalía de la interfase vitrerorretiniana (es decir, tracción vitreomacular, membranas epirretinianas, etc.) con posibilidad de daño estructural macular independientemente del proceso inflamatorio.
    25.Paciente con antecedentes de escleritis activa en los 12 meses anteriores a la SEL.
    Criterios relacionados con la comorbilidad
    26.Enfermedad inflamatoria intestinal no controlada.
    27.Infección que requiere tratamiento con antinfecciosos intravenosos (i.v.) en los 30 días previos al INI o antinfecciosos orales en los 14 días previos al INI.
    28.Paciente con algún tipo de infección activa que, según la evaluación clínica del investigador, haga que el paciente no sea un candidato idóneo para el ensayo.
    29.Antecedentes o cualquier signo de enfermedad linfoproliferativa, o neoplasia maligna conocida o antecedentes de neoplasia maligna en los 3 años anteriores (excepto carcinoma basocelular o de células escamosas que se hubiera extirpado completamente sin indicios de recidiva).
    E.5 End points
    E.5.1Primary end point(s)
    Part A: number and proportion of subjects with complete response at week 10
    Part B: "Time to Treatment Failure" (TTF) beyond week 10
    Parte A: número y proporción de sujetos con respuesta completa en la semana 10
    Parte B: "Tiempo hasta el fallo del tratamiento" (TTF) más allá de la semana 10
    E.5.1.1Timepoint(s) of evaluation of this end point
    Part A: week 10
    Part B: after week 10
    Parte A: Semana 10
    Parte B: despues de la semana 10
    E.5.2Secondary end point(s)
    Secondary endpoints supporting the primary objectives for Part B (Efficacy) related to the preventive part (>W10):
    • Change in ACC grade from best state achieved ≤W10 up to W50 or up to discontinuation due to Treatment Failure, if earlier Change in vitreous haze grade (NEI/SUN criteria) from best state achieved ≤W10 up to W50 or up to discontinuation due to Treatment Failure, if earlier
    • Change in BCVA using logarithm of the minimum angle of resolution (logMAR) calculation from best state achieved ≤W10 up to W50 or up to discontinuation due to Treatment Failure, if earlier
    • Change in central retinal thickness (by SD-OCT) from best state achieved ≤W10 up to W50 or up to discontinuation due to Treatment Failure, if earlier
    • In subjects with excess CST (by SD-OCT) at BL: Change in the reduction of BL excess CST from best state achieved ≤W10 up to W50 or up to discontinuation due to Treatment Failure, if earlier
    • Change in the NEI VFQ-25 score from best state achieved ≤W10 up to W50 or up to discontinuation due to Treatment Failure, if earlier
    • Change in the EQ-5D-3L score from from best state achieved ≤W10 up to W50 or up to discontinuation due to Treatment Failure, if earlier
    Secondary endpoints (Efficacy) related to the treatment of active disease (≤W10):
    • Change in ACC grade from BL to W10 or up to discontinuation due to Early Lack of Response, if earlier
    • Change in vitreous haze grade (NEI/SUN criteria) from BL to W10 or up to discontinuation due to Early Lack of Response, if earlier
    • Change in BCVA using logMAR calculation from BL to W10 or up to discontinuation due to Early Lack of Response, if earlier
    • Change in central retinal thickness (by SD-OCT) from BL to W10 or up to discontinuation due to Early Lack of Response, if earlier
    • Change of excess CST from BL to W10 or up to discontinuation due to Early Lack of Response, if earlier
    • Change in the NEI VFQ-25 score from BL over time (at least up to W10 or up to discontinuation due to Early Lack of Response, if earlier)
    • Change in the EQ-5D-3L score from BL over time (at least up to W10 or up to discontinuation due to Early Lack of Response, if earlier)
    Criterios secundarios de valoración que avalan los objetivos principales de la parte B (eficacia); relacionados con la parte preventiva (>S10):
    • Cambio en el grado de CCA a partir del mejor estado alcanzado ≤S10 hasta S50 o hasta la suspensión debida al fracaso terapéutico, si es anterior Cambio en el grado de turbidez del humor vítreo (criterios NEI/SUN) a partir del mejor estado alcanzado ≤S10 hasta la S50 o hasta la suspensión debida al fracaso terapéutico, si es anterior
    • Cambio en la MAVC utilizando el logaritmo del ángulo mínimo de resolución (logMAR) calculado a partir del mejor estado alcanzado ≤S10 hasta la S50 o hasta la suspensión debida al fracaso terapéutico, si es anterior
    • Cambio en el grosor retiniano central (por TCO-DE) a partir del mejor estado alcanzado ≤S10 hasta la S50 o hasta la suspensión debida al fracaso terapéutico, si es anterior
    • En pacientes con exceso del grosor del subcampo central (GSC) (por TCO-DE) al INI: cambio en la reducción del exceso del GSC inicial a partir del mejor estado de alcanzado ≤S10 hasta la S50 o hasta la suspensión debida al fracaso terapéutico, si es anterior
    • Cambio en la puntuación NEI VFQ-25 a partir del mejor estado alcanzado ≤S10 hasta la S50 o hasta la suspensión del tratamiento debida al fracaso terapéutico, si es anterior
    • Cambio en la puntuación del cuestionario EuroQOL-5D-3L a partir del mejor estado alcanzado ≤S10 hasta la S50 o hasta la suspensión debida al fracaso terapéutico, si es anterior

    Criterios secundarios de valoración (eficacia); relacionados con el tratamiento de la enfermedad activa (≤S10):
    •Cambio en el grado del CCA desde el INI a la S10 o hasta la suspensión debido a la ausencia de respuesta inicial, si es anterior
    • Cambio en el grado de turbidez del humor vítreo (criterios NEI/SUN) desde el INI hasta la S10 o hasta la suspensión debido a la ausencia de respuesta inicial, si es anterior
    • Cambio en la MACV mediante logMAR desde el INI hasta la S10 o hasta la suspensión debido a la ausencia de respuesta inicial, si es anterior
    • Cambio en el grosor retiniano central (mediante TCO-DE) desde el INI a la S10 o hasta la suspensión debido a la ausencia de respuesta inicial, si es anterior
    • Cambio en el exceso de GSC desde el INI a la S10 o hasta la suspensión debido a la ausencia de respuesta inicial, si es anterior
    • Cambio en la puntuación de NEI VFQ-25 desde el INI a lo largo del tiempo (al menos hasta la S10 o hasta la suspensión debido a la ausencia de respuesta inicial, si es anterior)
    • Cambio en la puntuación del cuestionario EuroQOL-5D-3L desde el INI a lo largo del tiempo (al menos hasta la S10 o hasta la suspensión debido a la ausencia de respuesta temprana, si es anterior)
    E.5.2.1Timepoint(s) of evaluation of this end point
    BL to W10 for Part A and W10 to W50 for Part B
    INI a S10 para la Parte A y S10 a S50 para la parte B
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    immunogenicity of ABY-035
    inmunogenicidad de ABY-035
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA32
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Austria
    France
    Germany
    Italy
    Spain
    Switzerland
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Subject Last Visit (LSLV)
    Última visita ultimo paciente (UVUP)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state28
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 87
    F.4.2.2In the whole clinical trial 110
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    When subjects complete the study, continuing treatment according to clinical routine will be provided as judged by the Investigator or treating physician.
    Cuando los sujetos completen el estudio, se les proporcionará un tratamiento continuado de acuerdo con la práctica clínica, según el criterio del investigador o del médico responsable del tratamiento.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-09-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-08-30
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 08 17:41:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA